Venus Medtech to Partner with Pi-Cardia to Bring its Leaflex(TM) Aortic Valve Technology to China
Jul 14, 2020, 06:11 ET
HANGZHOU, Chinaand REHOVOT,Israel,July 14, 2020/PRNewswire/ -- Venus Medtech (Hangzhou) Inc. (stock code: 2500.HK), the leading transcatheter heart valve medical device player in China,and Pi-Cardia Ltd., a global leader in the development of non-implant catheter-based solutions for treating heart valve calcification, announced today a collaboration to bring Pi-Cardia's Leaflex™ technology toChina.
Pi-Cardia's Leaflex™ catheter performs mechanical scoring of valve calcification, restoring leaflets' mobility and improving valve hemodynamics. The Leaflex™ catheter is designed to be a cost-effective, durable standalone treatment. It can be used for patients who are not planning to undergo transcatheter aortic valve replacement (TAVR) and it can be a means to defer TAVR in patients who may be too young for the procedure. It can also be a preparatory step for improving the outcome of TAVR in heavily-calcified and bicuspid aortic valves.
In April, Pi-Cardia closed aUS$27 millionfinancing led by Sofinnova Partners, a leading European life sciences venture capital firm, following the successful completion of its First-in-Human studies, which demonstrated acute safety and feasibility. The strategic agreement with Venus Medtech will enable Pi-Cardia to pursue its global expansion by working with the market leader inChinaon clinical trials, manufacturing and commercializing of its Leaflex™ technology, while concurrently continuing clinical trial activities inthe United StatesandEurope. For Venus Medtech, this collaboration represents a bolstering of its portfolio of aortic valve products, enabling it to offer a unique non-implant based solution, the first of its kind in the world, to a rapidly growing Chinese market.
"We are excited to collaborate with Pi-Cardia to bringing its unique Leaflex™ aortic valve repair technology to Chinese patients," saidEric Zi, Co-Founder and Chief Executive Officer of Venus Medtech. "The global aortic valve market is expected to reachUS$9 billionover the next few years, and we see a very steep growth in these procedures inChina. Our ability to offer a lower cost non-implant based solution for patients with calcified aortic valves is an important complement to our Venus TAVR platform, especially since patients inChinaare required to pay out of pocket for these procedures. Our ability to offer a safe and effective catheter-based repair of their valve will be attractive to many patients: either to defer the need for TAVR, or as a cost-effective alternative to TAVR or SAVR."
"We are thrilled to work with a strong industry partner to make Leaflex™ a reality inChina" saidErez Golan, Pi-Cardia's Chief Executive Officer and Founder. "With promising early clinical results, we are now ready to move to the next stage and establish the long term safety and efficacy of Leaflex™ as a standalone treatment for patients with aortic stenosis. We have an ambitious plan ahead of us, and we are dedicated to making Pi-Cardia's technology the next revolution in the treatment of structural heart disease."
"With large numbers of lower income aortic stenosis patients inChina, the Leaflex™ technology could provide treatment possibilities to an otherwise overlooked and undertreated sector," commented Academician Runlin Gao of Fuwai Hospital Chinese Academy of Medical Sciences and the National Center for Cardiovascular Diseases. Fuwai Hospital Chinese Academy of Medical Sciences is the world's largest cardiovascular center performing more than 75 thousand procedures each year. His colleague, ProfessorYongjian Wu, added, "We believe that The Leaflex™ system may also hold the promise of restoring leaflet mobility in calcified prosthetic valves and could be a viable alternative to future Valve-In-Valve procedures."
Pi-Cardia is a global leader in the development of unique non-implant-based solutions for treating valve calcification. Pi-Cardia's lead product, the Leaflex™ Performer catheter, is easily delivered and positioned on the valve, to then mechanically score the calcification at multiple locations, restoring leaflets flexibility and improving valve hemodynamics. The Leaflex™ catheter is designed to be a cost-effective, durable standalone treatment or a preparatory step to improve the outcome of valve implantation in heavily calcified aortic valves, and in bicuspid aortic valves. For more information, please visit:www.pi-cardia.net
About Venus Medtech (Hangzhou) Inc.
Venus Medtech (Hangzhou) Inc. was founded in 2009 to focus on the design, development and commercialization of transcatheter heart valve products. The Company is the leading transcatheter heart valve medical device player in China in terms of implantation volume in 2018. According to Frost & Sullivan, the Company had a 79.3% market share in China by implantation volume of transcatheter aortic heart valve replacement ("TAVR") products in 2018. Its self-developed product, VenusA-Valve, is the first TAVR product approved by the National Medical Products Administration ("NMPA") and commercialized in China. As the pioneer in the transcatheter heart valve industry in China, the Company enjoys first mover advantages. The Company believes that its first mover advantages, together with its comprehensive product pipeline covering all four heart valves, robust intellectual property portfolio with 193 issued patents and 196 patent applications as of November 18, 2019, and visionary management team, will serve as high entry barriers and differentiate the Company from its peers.